Loading...
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...
Saved in:
| Published in: | Biomedicines |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168248/ https://ncbi.nlm.nih.gov/pubmed/32019149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8020022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|